Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Immunolex is a Russian pharmaceutical company and manufacturing plant based in Moscow, primarily known for the production of Derinat (sodium deoxyribonucleate). Derinat is a unique DNA-based immunomodulator and reparative agent extracted from natural sources, used to treat a wide range of conditions including respiratory infections, chronic inflammatory diseases, and non-healing wounds. The company operates as a key manufacturing site for CJSC FP Technomedservice, focusing on the development and supply of immunotropic and regenerative therapies. Immunolex's products are widely utilized in clinical practice across Russia and the CIS for their ability to stimulate both innate and adaptive immunity through the activation of Toll-like receptor 9 (TLR9).
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Immunolex.